Risks in Biotech Investing: Lessons from Savara and Best Governance Practices

The biotechnology industry is facing increased scrutiny and litigation risks, with the case of Savara Inc. serving as a prime example of the challenges faced by companies in this sector. A class action lawsuit filed against Savara alleges that the company misled investors by concealing critical flaws in its Biologics License Application (BLA) for MOLBREEVI, leading to a significant stock collapse following the FDA’s refusal to file the application in 2025. This case highlights the risks associated with regulatory setbacks and lack of transparency in disclosures within the biotech industry.

Securities lawsuits against biotech firms have been on the rise, accounting for 17% of all securities class action filings in 2024. However, courts have become increasingly skeptical of cases lacking proven scienter, emphasizing the importance of precise and transparent communication from biotech executives, especially when disclosing complex scientific or regulatory information. The trend of dismissals in cases against firms like BioXcel, Revance, and AcelRx underscores the need for companies to maintain clear and accurate communication with their stakeholders.

Poor governance structures in the biotech industry can exacerbate litigation risks, as seen in the case of Altimmune Inc., where allegations of misrepresentation of clinical trial results led to a significant stock drop. Companies must prioritize board independence, rigorous data validation, and transparent shareholder communication to mitigate such risks. Internal confidence in public statements is crucial, as even unintentional errors can lead to scrutiny and liability.

Investors looking to navigate the complexities of the biotech sector must adopt multidisciplinary due diligence frameworks. This includes thorough validation of clinical data, assessment of governance metrics, and evaluation of regulatory readiness to meet FDA or EMA requirements. Diversification of portfolios is also essential to mitigate risks in a volatile sector where concentrated investments in unproven therapies can lead to massive losses.

In conclusion, proactive governance reforms, enhanced internal review processes, and legal risk assessments are vital for biotech companies to navigate regulatory and investor scrutiny successfully. By prioritizing transparency, accountability, and accurate communication, firms can build trust with stakeholders and avoid the legal and financial turmoil that can result from regulatory setbacks and litigation risks in the biotechnology industry.